Allarity Therapeutics amends convertible notes to cap conversion at 19.9% without stockholder approval

Allarity Therapeutics, Inc.

Amendment dated Feb 27, 2024 between Allarity and holder 3i, LP modifies two senior convertible notes from Jan and Feb 2024.
New provision bars conversion or share issuance if it would exceed 19.9% of outstanding common stock absent stockholder approval.
All other terms of the Notes remain in full force and effect.
Company also furnished an updated corporate presentation on its website (no specific material details provided in this filing).

item 1.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Allarity Therapeutics, Inc. amended Amendment to Senior Convertible Notes with 3i, LP (effective 2024-02-27).

Action: amendment
Agreement: notes offering
Counterparty: 3i, LP
Effective: 2024-02-27

Exact text from the filing

On February 27, 2024, Allarity Therapeutics, Inc., a Delaware corporation (“we,” “our,” or the “Company”) and 3i, LP, a Delaware limited partnership, (the “Holder” and together with us, the “Parties”) entered into an Amendment to Senior Convertible Notes (the “Amendment”) to two senior convertible notes dated as of January 18, 2024 and February 13, 2024

View on SEC.gov

737 material agreements filed in the last 30 days. Browse all material agreements →

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-018789

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.